Amisulpride


Concise Prescribing Info
Indications/Uses
Acute psychosis.
Dosage/Direction for Use
Adult: PO 400-800 mg bid. Max: 1.2 g/day. Patients w/ predominantly negative symptoms: 50-300 mg/day.
Administration
Should be taken on an empty stomach. Preferably taken before meals.
Contraindications
Phaeochromocytoma, concomitant prolactin-dependent tumours (e.g. pituitary gland prolactinomas or breast cancer). Pre-pubertal childn. Combination w/ levodopa.
Special Precautions
Patient w/ history of epilepsy; Parkinson's disease, CV disease. Avoid abrupt withdrawal. Renal impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause somnolence, if affected, may impair ability to drive or operate machinery.
Adverse Reactions
Insomnia, anxiety, agitation, drowsiness, wt gain, acute dystonia, parkinsonism, akathisia, tardive dyskinesia, QT prolongation, hypotension, bradycardia, GI disorders (e.g. constipation, nausea, vomiting, dry mouth), hyperglycaemia; breast pain, erectile dysfunction, amenorrhoea, gynaecomastia, galactorrhoea. Rarely, allergic reactions, abnormal LFTs, seizures.
Potentially Fatal: Neuroleptic malignant syndrome.
Drug Interactions
Increased risk of arrhythmias w/ cisapride, thioridazine, halofantrine, erythromycin, some antiarrhythmics, pimozide, haloperidol, TCAs, β-blockers, some Ca channel blockers, clonidine, guanfacine, digoxin, K-depleting diuretics, lithium, antimalarials. May enhance effects of antihypertensives and CNS depressants (e.g. sedative H1-antihistamines, narcotics, anaesth, analgesics, barbiturates, benzodiazepines, other anxiolytics, clonidine and derivatives).
CIMS Class
ATC Classification
N05AL05 - amisulpride ; Belongs to the class of benzamides antipsychotics.
Disclaimer: This information is independently developed by CIMS based on amisulpride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in